Immunome Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.8%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$444.4Knext fiscal year
FY EPS (est.)
-$2.31next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
| Full Year 2026 Earnings Release | 2 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly582.7MTarget: Sufficient to fund operations into 2028
Quarterly Net Loss Quarterly-53.8MTarget: Narrowing losses post-commercialization
Quarterly Research and Development Expenses Quarterly46.4MTarget: Optimized pipeline investment
Watch Items
- FDA Regulatory Approval of VaregacestatTrigger: NDA submitted in April 2026; FDA decision expected within standard review timelineAction: Prepare commercial launch infrastructure and scale up manufacturing
- EMA Regulatory Submission of VaregacestatTrigger: Marketing Authorization Application (MAA) submission planned by end of 2026Action: Coordinate European regulatory and commercial readiness
- IM-1021 Phase 1 Clinical Trial ProgressTrigger: Initial clinical data expected in 2026Action: Evaluate safety, tolerability, and preliminary efficacy in B-cell lymphoma
- IM-1617 Phase 1 Clinical Trial ProgressTrigger: First patient dosed in June 2026Action: Monitor safety, tolerability, and pharmacokinetics in advanced solid tumors
- Preclinical ADC Pipeline IND SubmissionsTrigger: IND submissions for IM-1340 and IM-1335 planned for mid- and late-2026Action: Complete IND-enabling studies and prepare clinical trial protocols
Research as of 20 Jun 2026